Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

1697 - Illness perceptions, quality of life and mood in metastatic breast cancer patients


29 Sep 2019


Poster Display session 2


Tumour Site

Breast Cancer


Isabel Domingues


Annals of Oncology (2019) 30 (suppl_5): v104-v142. 10.1093/annonc/mdz242


I. Domingues, J. Carvalho, E.A. Pratas, S. Pinheiro, S. Amaral, T. Pereira, F. Pontes, R. Félix, A. Chaves, M. Mariano, T. Carvalho, P. Madeira, A. Pêgo, S. Broco, R. Garcia, I. Pazos, A. Pais, G. Sousa

Author affiliations

  • Medical Oncology, Portuguese Institute of Oncology of Coimbra, 3000-075 - Coimbra/PT


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1697


The patients’ (pts) illness perception is based on dimensions of cognitive understanding and emotional representations of disease and its symptoms. Previous studies reported that illness perceptions influence quality of life (QoL) and mood.


212 pts with metastatic breast cancer, under treatment, were evaluated by Illness Perception Questionnaire Brief version (IPQ-B), EORTC Quality of Life Questionnaire (QLQ-30) and Hospital Anxiety and Depression Scale (HADS). IPQ-B higher scores indicate a negative perception. EORTC QLQ-30 higher scores indicate better functioning/QoL or worse symptom severity. Higher HADS indicate higher anxiety/depression (AD) levels. Variables were studied using Pearls correlation (Sig 0.01) and T test. Primary endpoint was evaluation of illness perception. Secondary endpoints were assessment of pts characteristics, QoL, AD and its associations with illness perception.


Median age was 64 years (y) and 99.5% (211 pts) were women. Median IPQ-B score was 18/32. All patients reported that their breast cancer is incurable. Perception of disease consequences was more negative in pts younger than 70y versus 70y or older (2.7 vs 2.3, p = 0.039). Preoccupation and perception of control with treatment were higher in younger pts (3.4 vs 2.9, p = 0.004; 3.6 vs 3.3, p = 0.03; respectively). Pts under chemotherapy and/or anti-HER2 therapy shown a greater impact of disease consequences, than pts under endocrine therapy and/or other target therapies (2.6 vs 2.3, p = 0.039). The mean overall QoL was 54.6/100 (± 23.0). Physical, cognitive, social and emotional functioning mean scores were respectively 60.3, 69.1, 69.3 and 60.3/100; all lower than EORTC ref. values (p < 0.01). Social functioning and IPQ-B shown a moderate negative correlation (r = - 0.507). The mean HADS score was 16.9/42 (± 7.8), reflecting the AD subscales (respectively, 9.1/21; 7.8/21). The overall illness perception and HADS shown a moderate positive association (r = 0.62). Anxiety and the emotional dimension of IPQ-B had a moderate positive correlation (r = 0.598).


Integrating in clinical practice the relation between illness perceptions, QoL and AD, may improve disease’s coping mechanisms and functional capacity (physical, emotional, social).

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.